Lung infection or inflammation-a puzzling case of MDA-5 associated juvenile dermatomyositis.
Anusha VuppalaManush SondhiSarwat UmerPublished in: Pediatric rheumatology online journal (2023)
Juvenile dermatomyositis (JDM) remains a rare and intricate autoimmune disorder affecting young individuals. The presence of MDA5 antibodies in JDM patients can lead to severe complications like ILD, necessitating vigilant monitoring. Management includes immunosuppressive therapy, with glucocorticoids and mycophenolate mofetil proving effective, particularly in Clinically Amyopathic Dermatomyositis (CADM) cases. In cases of refractory disease, intravenous immunoglobulin (IVIG) plays a crucial role, offering a safe and beneficial adjunct to treatment. We emphasize the importance of recognizing atypical presentations of JDM, as it can lead to delays in diagnosis and treatment. Our case highlights the complexities of managing dual lung pathology, where a secondary infection exacerbated lung nodules and thrombocytopenia, while ILD was a consequence of atypical myopathy. Combining antifungal treatment with immunosuppression effectively managed both conditions and follow-up evaluations demonstrated improvement in ILD. Awareness of potential fungal infections in immunosuppressed JDM patients is crucial for successful treatment and patient outcomes.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- oxidative stress
- prognostic factors
- early onset
- stem cells
- high dose
- disease activity
- late onset
- systemic lupus erythematosus
- combination therapy
- cell proliferation
- patient reported outcomes
- mesenchymal stem cells
- drug induced
- replacement therapy
- cell therapy